COMPUTATIONAL BIOLOGY AND CHEMISTRY is a distinguished academic journal published by Elsevier Science Ltd, focusing on the dynamic intersection of computational biology, biochemistry, and chemistry. With an ISSN of 1476-9271 and an E-ISSN of 1476-928X, this journal is committed to disseminating high-quality research that employs computational techniques to solve complex biological and chemical problems. As of 2023, the journal holds a substantial impact factor reflecting its significance and rigorous peer-review process, categorized in the Q2 quartile for both Computational Mathematics and Organic Chemistry, alongside Q3 classifications in Biochemistry and Structural Biology. With a continuous publication history spanning from 2003 to 2024, it serves as a critical resource for researchers, professionals, and students alike. The journal offers various open access options, ensuring that vital research findings are accessible to a global audience, further enhancing collaboration across disciplines. Engage with cutting-edge studies and contribute to the evolving landscape of computational methodologies in the life sciences through this esteemed publication.

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH is a prestigious publication in the field of natural products, focusing on valuable research spanning analytical chemistry, pharmacology, and complementary medicine. Published by Taylor & Francis Ltd in the United Kingdom, this journal has established itself as a key resource for academics and professionals seeking to explore advancements in drug discovery and organic chemistry. With a converged publication timeline from 1998 to 2024, the journal boasts several commendable category quartiles as of 2023, reflecting its robust standing in the research community: Q2 in Complementary and Alternative Medicine, Q3 in multiple domains including Analytical Chemistry and Organic Chemistry, and Q4 in Molecular Medicine. Although it currently does not offer open access, the journal remains a valuable compendium for empirical research and innovative studies in areas such as pharmacology and medicinal chemistry. Researchers, professionals, and students alike will find the JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH to be an essential platform for sharing groundbreaking findings and fostering collaborations that lead to significant advancements in science and health.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, published by Taylor & Francis Ltd, is a premier open-access journal that has been at the forefront of research in the field of medicinal chemistry since its inception in 1985. With an ISSN of 1475-6366 and an E-ISSN of 1475-6374, this journal boasts a prestigious reputation reflected in its impressive Q1 rankings across critical categories such as Drug Discovery and Pharmacology as of 2023. Situated in the United Kingdom, it plays a vital role in disseminating high-quality research that addresses the burgeoning needs of drug discovery and enzyme inhibition methodologies. The journal supports full open access, providing a platform for researchers, professionals, and students to share significant findings and innovations widely. With a robust impact factor, the JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY is indispensable for any academic or professional involved in the pharmacological sciences, offering an unparalleled insight into the latest advancements in therapeutic strategies and drug development.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Molecular Informatics is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to advancing the fields of computational analysis and molecular modeling. As a key resource in the realms of Computer Science Applications, Drug Discovery, Molecular Medicine, Organic Chemistry, and Structural Biology, this journal is recognized for its significant contributions and is ranked in the Q2 and Q3 categories across multiple disciplines, positioning it among the leading journals for researchers and academics. With an impressive track record since its inception in 2010 and converging its contributions until 2024, Molecular Informatics aims to bridge the gap between computational techniques and biological applications, promoting interdisciplinary collaboration and innovation. Accessible to a global audience, the journal reflects a commitment to advancing science through open access options, making cutting-edge research available to students, professionals, and decision-makers alike. This journal serves as an indispensable platform for disseminating high-quality research and fostering the development of new theoretical and practical frameworks in molecular informatics.

Current Research in Structural Biology, published by Elsevier, is a pioneering Open Access journal that has rapidly gained prominence since its inception in 2019. With a focus on advancing the understanding of molecular and structural biology, this journal provides a platform for researchers and professionals to publish groundbreaking findings that contribute to the field's ongoing development. With a commendable Q2 ranking in both Molecular Biology and Structural Biology categories for 2023, it serves as a vital resource for the community, ensuring accessibility to high-quality research. The journal is indexed in Scopus, showcasing its significant impact and relevance, particularly with a ranking of #26/49 in the Structural Biology discipline. Located in the heart of the Netherlands, Current Research in Structural Biology not only fosters academic discourse but also encourages collaborative research efforts in addressing critical biological questions. Whether you are a researcher, student, or industry professional, this journal is essential for staying abreast of the latest advancements and trends in structural biology.

The Journal of Computational Biophysics and Chemistry, published by World Scientific Publishing Co. Pte Ltd, is a distinguished platform dedicated to advancing the fields of biophysics and computational chemistry. With an ISSN of 2737-4165 and an E-ISSN of 2737-4173, this journal has garnered attention since its inception, earning a Q3 ranking in Computational Theory and Mathematics and Q4 rankings in both Computer Science Applications and Physical and Theoretical Chemistry as of 2023. The scope of the journal encompasses innovative research that integrates computational techniques with biochemical applications, making it essential reading for researchers, professionals, and students alike. With open access options available, the journal ensures that cutting-edge findings are easily accessible to a global audience, thereby fostering collaboration and innovation in the scientific community. Based in Singapore, the journal aims to converge ideas and methodologies from 2021 to 2024, paving the way for transformative insights in computational methods. Join a community at the forefront of research and applications that bridge disciplines through rigorous scholarship and pioneering discoveries.

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.